What does this research mean for the field?

In patients with aggressive non-Hodgkin's lymphoma, those with stage IV T-cell immunophenotype have a significantly poorer complete remission rate and overall survival compared to those with B-cell lymphoma when treated with standard regimens. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

December 1, 1989Journal of Clinical Oncology

Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma.

View Full Paper

Ask AI

Bookmark

Authors

JAJamés O. ArmitageNorthwestern University JVJulie M. VoseNorthwestern University JLJ LinderUniversity of Maryland, Baltimore

Discussion

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Armitage et al. (1989) studied this question.

synapsesocial.com/papers/6aaa614a935e76905abe060d https://doi.org/10.1200/jco.1989.7.12.1783

View Full Paper

Ask AI

Bookmark

December 1, 1989Journal of Clinical Oncology

Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma.

View Full Paper

Ask AI

Bookmark

Authors

JAJamés O. ArmitageNorthwestern University JVJulie M. VoseNorthwestern University JLJ LinderUniversity of Maryland, Baltimore

Discussion

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Armitage et al. (1989) studied this question.

synapsesocial.com/papers/6aaa614a935e76905abe060d https://doi.org/10.1200/jco.1989.7.12.1783

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark